ArcticDx Licenses Colorectal Cancer Biomarker IP from UK's CRT

Jul 31, 2008

NEW YORK (GenomeWeb News) – Cancer Research Technology, the technology commercialization arm of Cancer Research UK, said today that it will license certain intellectual property related to colorectal cancer risk assessment to the molecular diagnostics company ArcticDx.

Under the non-exclusive license agreement, ArcticDx will pay CRT an upfront payment and royalties from any sales of the biomarker-based test it plans to develop using the technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Halt Under Consideration

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

How's It Going to Go Over?

The Associated Press reports that gene-edited food may soon be for sale.

Meetings on Fetal Research

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

This Week in Cell

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.

Main menu